NASDAQ:TARS Tarsus Pharmaceuticals Q3 2026 Earnings Report $74.00 -0.46 (-0.61%) As of 01:35 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tarsus Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$1.49Beat/MissN/AOne Year Ago EPSN/ATarsus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$182.74 millionBeat/MissN/AYoY Revenue GrowthN/ATarsus Pharmaceuticals Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateTuesday, November 3, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Tarsus Pharmaceuticals Earnings HeadlinesTarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options4 hours ago | seekingalpha.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street BrokeragesOctober 5 at 2:28 AM | americanbankingnews.comFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises new questions about how protected everyday bank accounts and retirement savings really are.October 6 at 1:00 AM | Priority Gold (Ad)Head-To-Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) & Astrazeneca (NYSE:AZN)October 4 at 3:58 AM | americanbankingnews.comTarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...September 29, 2026 | markets.businessinsider.comTarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual MeetingSeptember 29, 2026 | globenewswire.comSee More Tarsus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tarsus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tarsus Pharmaceuticals and other key companies, straight to your email. Email Address About Tarsus PharmaceuticalsTarsus Pharmaceuticals (NASDAQ:TARS) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company concentrates on areas of significant unmet need in ophthalmology and aims to address conditions that can affect ocular health, comfort and vision. Tarsus’ primary product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis. The condition is associated with an infestation of Demodex mites and can cause eyelid inflammation, irritation and other ocular symptoms. XDEMVY is the first FDA-approved treatment specifically indicated for Demodex blepharitis. Founded in 2016 and headquartered in Irvine, California, Tarsus markets XDEMVY in the United States and continues to develop additional ophthalmic therapies. The company is led by President and Chief Executive Officer Bobak R. Azam, M.D., who has experience in the biotechnology and pharmaceutical industries.View Tarsus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
